Bone Metastasis Disease from Mucinous Carcinoma of the Breast
A Rare Case Report with Immunohistochemical Confirmation
DOI:
https://doi.org/10.56260/sciena.v4i1.194Keywords:
Mucinous breast carcinoma, bone metastasis, immunohistochemistry, GATA3, skeletal metastasesAbstract
Background: Mucinous carcinoma of the breast (MCB) is a rare histological subtype of invasive breast cancer, comprising 1-7% of all breast carcinomas. It is generally associated with a favorable prognosis due to its indolent course and low metastatic potential. However, distant metastases, including to the bone, are exceptionally rare and pose diagnostic and therapeutic challenges. Case Presentation: We present a case of a 64-year-old woman with a history of MCB who developed progressive back pain and lower limb weakness. MRI showed multiple osteolytic lesions with spinal cord compression. A CT-guided biopsy confirmed metastatic mucinous carcinoma, and immunohistochemical (IHC) staining demonstrated GATA3 positivity, confirming breast origin. The patient received denosumab, aromatase inhibitors, and palliative radiotherapy. Conclusion: This case highlights the importance of considering bone metastases in patients with a history of MCB presenting with skeletal-related events. IHC, particularly GATA3, is crucial in confirming the metastatic origin and guiding targeted treatment strategies.
References
B. Solid and T. Rules, “Breast Equivalent Terms and Definitions C500-C506, C508-C509 (Excludes lymphoma and leukemia M9590 – M9993 and Kaposi sarcoma M9140) Introduction,” vol. 509, no. September 2021, pp. 1–45, 2018.
X. Zhou et al., “The clinical features and prognosis of patients with mucinous breast carcinoma compared with those with infiltrating ductal carcinoma: a population-based study,” BMC Cancer, vol. 21, no. 1, pp. 1–9, 2021, doi: 10.1186/s12885-021-08262-0.
S. Di Saverio, J. Gutierrez, and E. Avisar, “A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma,” Breast Cancer Res. Treat., vol. 111, no. 3, pp. 541–547, 2008, doi: 10.1007/s10549-007-9809-z.
A. C. W. Lee et al., “Mucinous Carcinoma of the Breast: imaging Features and Pathological Correlation,” Hong Kong J. Radiol., vol. 21, no. 1, pp. 25–33, 2018, doi: 10.12809/hkjr1616821.
M. Jung, “Mucinous carcinoma of the breast: distinctive histopathologic and genetic characteristics,” Kosin Med. J., vol. 37, no. 3, pp. 176–186, 2022, doi: 10.7180/kmj.22.022.
C. L. Ellis et al., “GATA-3 immunohistochemistry in the differential diagnosis of Adenocarcinoma of the urinary bladder,” Am. J. Surg. Pathol., vol. 37, no. 11, pp. 1756–1760, 2013, doi: 10.1097/PAS.0b013e31829cdba7.
Y. Wei, S. Liu, M. Zhang, X. Ke, M. Chen, and B. Wei, “Clinicopathologic characteristics of HER2-positive pure mucinous breast carcinoma : a systematic investigation into an unusual tumor,” vol. 12, no. 5, pp. 1666–1677, 2019.
S. S. Gloria Kang GJ, Ewing-Nelson SR, Mackey L, Schlitt JT, Marathe A, Abbas KM, “乳鼠心肌提取 HHS Public Access,” Physiol. Behav., vol. 176, no. 1, pp. 139–148, 2018, doi: 10.1002/cncy.22226.Hormone.
O. Peyruchaud, “Mechanisms of bone metastasis formation,” J. Soc. Biol., vol. 201, no. 3, pp. 229–236, 2007, doi: 10.1051/jbio:2007033.
W. Yang, Q. Pan, F. Huang, H. Hu, and Z. Shao, “Research progress of bone metastases: From disease recognition to clinical practice,” Front. Oncol., vol. 12, no. January, pp. 1–14, 2023, doi: 10.3389/fonc.2022.1105745.
F. Malberti and M. Foramitti, “Denosumab: Renal Safety Evaluation,” J. Onco-Nephrology, vol. 1, no. 2, pp. 127–131, 2017, doi: 10.5301/jo-n.5000016.
X. Wang, K. H. Yang, P. Wanyan, and J. H. Tian, “Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: A meta-analysis of randomized controlled trials,” Oncol. Lett., vol. 7, no. 6, pp. 1997–2002, 2014, doi: 10.3892/ol.2014.1982.
P. Guha and Z. Chowdhury, “Metastasis of mucinous breast carcinoma to the lower alveolus as initial presentation: a diagnostic dilemma,” Autops. Case Reports, vol. 12, pp. 1–6, 2022, doi: 10.4322/acr.2021.407.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Hera Novianti, Pamelia Mayorita, Meta Zulyati Oktora, Ataya Hafizhah, Almu Muhammad
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
